RECOVERY Trial Finds No Clinical Benefit Of Lopinavir-Ritonavir Usage For COVID-19 Patients

The RECOVERY Trial has found that the HIV antiviral lopinavir-ritonavir has no clinical benefits when used for treatment of hospitalised COVID-19 patients. 1,596 randomised patients were treated with lopinavir-ritonavir while 3,376 randomised patients were given the usual care. Researchers found that the antiviral had no effect on use of ventilators or length of hospital stay in test subjects.